In This Issue...  by Emanuel, Janet Rettig
ACKNOWLEDGMENT 
ur Thanks to Hoechst-Roussel Pharmaceuticals Inc. 
We recognize with appreciation Hoechst-Roussel Pharmaceuticals Inc. for 
ledging support to the Endowment Fund for The Journal of Investiga-
've Dennatology, which will be used to support the growth and continued ~ccess oj the JO/jrnal. This support will ~erta.i'lly strengthen a.nd perp~tu.ate 
he partnersh~p between the fharmaceutlCalllldustry and baSIC and cl,nICal 
investigators III cutaneous bIOlogy. 
In This Issue • • • 
Janet Rettig Emanuel 
We salute Hoechst-Roussel Pharmaceuticals Inc. for their contribution to 
the Endowment FUlld alld for their continued support of clinical and illves-
tigative dermatology. 
EJ. O'Keefe, Chapel Hill, NC 
IN THIS ISSUE 
Molecular Dissection of the Keratins 
Intermediate filaments (IF) are complex elements of the cellular 
cytoskeleton. In epidermal cells, they are primarily composed of 
'eterodiITlers between molecules. o~ acidic type I an~ neutral-basic 
Jtype II keratins. Further axso~latlon produces a highly ordered 
dirner-to-dimer network of fibnls and filaments. St~cturally, ker~­
tins are similar in that they all possess ~ central a-helLcal rod domam 
that is highly conserved and N-termmal and C-termmal flankmg 
domains that account for the major variations between and within 
classes. The rod domains are responsible for dimerization, and the 
terminal domains influence the pattern of macromolecular as-
sembly. 
Clusters of type I genes are located on chromosome 12q, whereas 
tYpe II genes are found on chromosomes 17q. Point mutations and 
deletions have been identified in both classes of keratin genes, some 
of which are directly linked to dominantly inherited blistering der-
matoses. For a report on C-terminal deletion-associated alleles of 
K 1 and K10, see JID 99:697 - 702, 1992 (December).- In this issue, 
Wanner et al (p. 735) examine the variability in type II keratins at 
the nucleic acid level using the elegant technique of single-strand 
conformation polymorphism (SSCP) detection. . .. 
They found that proteins from squamous non-kerattmz.mg 
epithelia demonstrated polymorphism in the K4 and K5 protems. 
Analysis of the coding sequences for their cDNAs demonstrated 
that the rod segment and C-termini were relatively homogenous 
but that within the N-terminal domain of both proteins there ex-
isted at least three alleles resulting from mutations and deleti.ons 
with significant representation in the population. Each exhibited 
Mendelian inheritance. These allelic differences will expand the 
linkage markers available within the keratin gene clusters and may 
also be helpful in analysis of the relationship between the type II 
keratins and other genes involved in disorders of epithelial differen-
tiation. 
A Model for the Study of Kaposi's Sarcoma 
Kaposi's sarcoma is a complex multifocal neoplasm containing vas-
cular structures, spindle cells, and an inflammatory infiltrate. To 
date, researchers have been unable to determine the "cell of origin" 
by comparing tumor cell markers with marker profiles of normal 
cells. In this issue, O'Connell and Rudmann (p. 742) atJohns Hop-
kins describe a model system designed to bypass this critical stum-
bling block. An established murine microvascular cell line was 
stably transformed with SV~40 viru.s and then ~nj~cted i~to immun-
odeficient nude (nujnu) mice. ThiS resulted m mductlon of non-
metastatic tumors resembling Kaposi's sarcoma. These tumors con-
tained spindle cells and microvascular structures. Becuase mouse 
cells are non-permissive for SV-40 infection but produce the asso-
ciated T -antigen at high levels in the nuclei of progeny of the 
transfected cells, this approach provides viral marker detectable by 
antibody and allows identification of the tumor cells. Initial cloning 
of cells from the induced tumors produced an epitheloid cell line 
that expressed endothelial markers as well as the viral antigen. The 
cell. line maintained its transformed phenotype and produced K~­
pOSl'S sarcoma-like tumors in nude mice. Cloning from the ongl-
nal tumors later established an initially slower-growing cell line 
with spindle-cell morphology. These cells also produced tumors 
with Kaposi's sarcoma -like progression. Subsequently, third-g~ner­
ation cell lines have been subcloned from the epithelioid and spmdle 
cell- induced tumors. Each line is morphologically distinct and un-
like the original isolates, and each expresses the viral antigen and the 
histocompatibility marker of the transformed progenitor cells. T~ls 
study demonstrates that Kaposi's sarcoma-like lesions can be m-
duced by virally transformed endothelial cells and that cell ~p~s 
with both cuboidal and spindfe morphologies are established wlthm 
the tumors. Because these cell types are stable in vitro, they can .be 
further used to study the genetic and epigenetic feature.s that contrib-
ute to endothelial differentiation and to tumorogeneSlS. The results 
of this work may well provide important information about the 
basic biology of Kaposi's sarcoma. 
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On the Role of p53 in Squamous Cell Skin Cancers 
p53 is a "tumor suppressor" gene, whose product negatively regu-
lates cellular proliferation by inhibiting cells from passing the G1 
boundary of the cell cycle. Under normal circumstances, this allows 
cells to repair damage sccrued in interphase before DNA synthesis 
replicates the problem and mitosis passes it on to daughter cells. 
Mutations in this gene are commonly found in human cancers and 
are suggested to be responsible for altered growths, because a de-
crease in function of p53 protein may lead to deregulated cellular 
growth, the accumulation of DNA damage, and cancer. Bowen's 
disease, in sit I< carcinoma that can lead to invasive carcinoma, tends 
to arise on skin that has been exposed to sun damage. 
Immunocytochemistry has been used to detect altered p53 pro-
teins, since many of the mutations in the p53 coding region result in 
a structurally altered, inactivated protein that has a longer half-life 
that normal protein. This often results in high levels of protein that 
is detectable by antibody in im,munofluorescence studies. But inac-
tivation of the p53 protein can occur by other means, including 
mutation in the regulatory domains of the p53 gene or changes in 
other genes that affect the function of p53 protein. Bowen's disease 
has been previously associated with positive p53 immunoreactivity. 
In this issue, Campbell et al (p. 746) have sequenced the most com-
monly mutated regions of the p53 coding sequences to determine 
the incidence of mutations in this gene to examine the role of p53 in 
the progression to squamous cell carcinoma. Their data confirm that 
nearly 50% of the lesions contain detectable p53 coding region 
mutations. Further, the mutations occur at known hot spots for 
mutation within this gene, and the nature of the mutations is consist-
ent with ultraviolet-induced DNA damage. The pattern of expres-
sion of the mutations suggests that they are an early event in the 
development of this neoplasm and generally precede invasive be-
havior. 
Extended HLA Haplotype: A Genetic Marker for Diagnosis of Psoriasis 
In addition to the hyperproliferation, one of the major characteris-
tics of psoriasis is the presence of inflammatory cells within the 
dermis and epidermis of patients. An association has been described 
recently between the presence of specific human leukocyte antigens 
(HLAs) and two groups of patients with psoriasis. This has led to the 
idea that psoriasis has two major types: type I, with early onset and a 
family history, and type II, which has a later onset and is not famil-
ial. The HLAs are a highly polymorphic multigene family. Class I 
antigens (A,-B, and C group alleles) are ubiquitously expressed and 
can form a complex with intracellular viral and tumor antigens, 
which are then presented at the cell surface for recognition by 
CD8+ cytolytic T-cell receptors. Class II antigens (multiple D 
region alleles) are expressed on fewer cell types and can form a 
complex with extracellular peptide antigens for presentation to re-
ceptors on CD4+ helper T cells. The class II HLA profile of an 
individual is genetically determined and highly complex. Because 
the T cells found in psoriatic lesions are primarily of the CD4+ 
subset, Schmitt-Egenolf and co-workers at the University of Ulm 
(p . 749) analyzed the HLA types of patients with chronic stable type 
I and type II psoriasis. Class I HLA analysis was by serologic profile 
and class II HLA analysis was by sequence-specific oligonucleotide 
hybridization to dot blots of amplified DNA. The results show a 
striking correlation of class II HLA extended haplotype with the 
diagnosis of type I psoriasis. This indicates a very strong genetic 
linkage between psoriasis and class II HLA genes. This finding 
suggests that at least one group of patients with psoriasis can be 
distinguished by objective means and may provide an important 
advance towards understanding the pathogenesis of psoriasis. 
Promoting the Expression of ICAM-l 
Cellular adhesion molecules (CAMs) are surface membrane pro-
teins that promote recognition of many different cell types. This 
recognition is an important aspect ofleukocyte migration in inflam-
matory and wound repair responses as well as in tumor invasion. In 
different cell types, the genes for these adhesion molecules can be 
expressed constitutively, repressed, or differentially induced by 
various cytokines. ICAM-l is constitutively expressed by human 
dermal microvascular endothelial cells (HDMECs) and induced to 
higher levels of expression by y-interferon, tumor necrosis factor, or 
interleukin-l. Human keratinocytes do not normally express 
ICAM-l; they are inducible by y-IFN or TNF, but not by IL-l. 
Therefore, this gene shows cell type- and inducer-specific expres-
sion. The genetic control elements that influence expression of any 
protein act in a number of ways. A cis-acting element is a DNA 
sequence near the coding sequence for a gene that allows or disal-
lows expression of a gene product. A trans-acting factor is a separate 
gene product that interacts with controlling regions of a gene to 
repress or stimulate activity of the target gene. 
In this issue, (Cornelius et ai, p. 753) a region of the ICAM-l 
genomic DNA sequence, upstream from the transcription start sig-
nal is functionally dissected for domains that contribute to the ob-
served variations in the level ofICAM-l expression. Chloramphen-
icol acetyl-transferase (CAT) coding sequence is used to "report" 
the contribution of 5' -flanking regions to the level of expression of 
the gene. Plasmids constructed with candidate DNA sequences, 
sequences that might control expression of ICAM-l, followed by 
"CAT" were transfected into cultured cells, and the expressed CAT 
enzyme activity was measured by thin-layer chromatographic de-
tection of acetylated 14C-labeled chloramphenicol. In this way, each 
construct was evaluated for the contribution of the candidate DNA 
sequence, the nature of the recipient cell type, or the activity of a 
potentialcytokine effector. The data show that DNA closely flank-
ing the ICAM-l gene product contains a region that represses ex-
pression in a keratinocyte cell line and enhances expression in 
HDMEC. Cell s bearing constructs that encompass a larger frag-
ment of flanking sequence more closely mimic the in vivo ICAM-l 
profile, both in the basal levels of ICAM produced and in the levels 
that are detected after treatment of the transfectants with cytokines. 
These studies will help us to understand, for example, how adhesion 
of leukocytes to endothelial cells is controlled during the develop-
ment of an inflammatory response. 
